Chemcrux Enterprises Ltd
Incorporated in 1996, Chemcrux Enterprises Ltd manufactures and processes bulk drug intermediates[1]
- Market Cap ₹ 207 Cr.
- Current Price ₹ 140
- High / Low ₹ 251 / 100
- Stock P/E 49.4
- Book Value ₹ 51.4
- Dividend Yield 0.70 %
- ROCE 7.41 %
- ROE 5.65 %
- Face Value ₹ 10.0
Pros
- Company has been maintaining a healthy dividend payout of 24.5%
Cons
- The company has delivered a poor sales growth of 4.10% over past five years.
- Company has a low return on equity of 13.0% over last 3 years.
- Working capital days have increased from 118 days to 196 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
15.61 | 19.60 | 20.09 | 27.43 | 31.45 | 55.27 | 57.45 | 53.33 | 95.27 | 95.15 | 78.47 | 70.25 | |
14.05 | 17.39 | 16.94 | 23.98 | 26.72 | 41.09 | 42.67 | 40.77 | 74.56 | 73.69 | 65.10 | 61.18 | |
Operating Profit | 1.56 | 2.21 | 3.15 | 3.45 | 4.73 | 14.18 | 14.78 | 12.56 | 20.71 | 21.46 | 13.37 | 9.07 |
OPM % | 9.99% | 11.28% | 15.68% | 12.58% | 15.04% | 25.66% | 25.73% | 23.55% | 21.74% | 22.55% | 17.04% | 12.91% |
0.03 | 0.06 | 0.07 | 0.31 | 0.29 | -0.30 | 0.90 | 0.84 | 1.00 | 1.05 | 1.18 | 1.53 | |
Interest | 0.45 | 0.42 | 0.26 | 0.35 | 0.31 | 0.28 | 0.32 | 0.15 | 0.17 | 0.82 | 0.83 | 1.64 |
Depreciation | 0.50 | 0.55 | 0.50 | 0.55 | 0.67 | 1.26 | 1.18 | 1.20 | 1.59 | 2.04 | 2.29 | 3.13 |
Profit before tax | 0.64 | 1.30 | 2.46 | 2.86 | 4.04 | 12.34 | 14.18 | 12.05 | 19.95 | 19.65 | 11.43 | 5.83 |
Tax % | 31.25% | 34.62% | 29.27% | 47.55% | 41.58% | 24.55% | 24.96% | 25.81% | 25.51% | 26.92% | 26.16% | 28.13% |
0.43 | 0.85 | 1.74 | 1.50 | 2.36 | 9.32 | 10.64 | 8.93 | 14.86 | 14.36 | 8.44 | 4.19 | |
EPS in Rs | 0.80 | 1.57 | 3.22 | 1.01 | 1.59 | 6.30 | 7.19 | 6.03 | 10.03 | 9.70 | 5.70 | 2.83 |
Dividend Payout % | -0.00% | 5.29% | 2.59% | 8.23% | 5.23% | 2.65% | 18.57% | 11.06% | 19.93% | 20.63% | 17.55% | 35.35% |
Compounded Sales Growth | |
---|---|
10 Years: | 14% |
5 Years: | 4% |
3 Years: | -10% |
TTM: | -10% |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | -17% |
3 Years: | -34% |
TTM: | -50% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 40% |
3 Years: | -9% |
1 Year: | -40% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 17% |
3 Years: | 13% |
Last Year: | 6% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.80 | 1.80 | 1.80 | 4.94 | 4.94 | 4.94 | 4.94 | 4.94 | 14.81 | 14.81 | 14.81 | 14.81 |
Reserves | 4.00 | 4.76 | 6.77 | 7.54 | 9.75 | 18.92 | 27.48 | 35.92 | 39.87 | 51.60 | 57.45 | 61.30 |
3.46 | 2.69 | 3.61 | 4.00 | 3.73 | 2.94 | 1.92 | 0.93 | 9.11 | 14.43 | 26.46 | 26.81 | |
4.53 | 4.62 | 2.96 | 4.11 | 8.37 | 11.81 | 10.20 | 6.90 | 19.32 | 12.38 | 11.15 | 9.23 | |
Total Liabilities | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 |
6.94 | 7.07 | 7.54 | 8.29 | 10.75 | 11.24 | 15.40 | 19.37 | 24.32 | 33.11 | 33.09 | 57.55 | |
CWIP | -0.00 | -0.00 | -0.00 | 0.21 | -0.00 | -0.00 | -0.00 | 0.32 | -0.00 | 0.31 | 21.06 | 1.61 |
Investments | 0.05 | 0.05 | 0.05 | 0.05 | 1.07 | 3.89 | 6.53 | 9.35 | 7.09 | 16.79 | 19.83 | 19.84 |
6.80 | 6.75 | 7.55 | 12.04 | 14.97 | 23.48 | 22.61 | 19.65 | 51.70 | 43.01 | 35.89 | 33.15 | |
Total Assets | 13.79 | 13.87 | 15.14 | 20.59 | 26.79 | 38.61 | 44.54 | 48.69 | 83.11 | 93.22 | 109.87 | 112.15 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1.18 | 1.52 | 0.83 | 1.41 | 3.50 | 8.05 | 10.90 | 9.62 | 9.14 | 14.82 | 16.54 | 7.07 | |
-0.66 | -0.72 | -0.97 | -1.45 | -4.17 | -5.18 | -7.62 | -8.16 | -2.64 | -20.48 | -25.85 | -7.93 | |
-0.64 | -0.29 | -0.07 | 1.94 | -0.07 | -1.23 | -3.56 | -0.76 | 2.76 | 0.96 | 7.40 | -3.18 | |
Net Cash Flow | -0.11 | 0.51 | -0.22 | 1.90 | -0.74 | 1.64 | -0.29 | 0.69 | 9.26 | -4.70 | -1.91 | -4.04 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 59.63 | 42.46 | 65.22 | 56.69 | 74.28 | 71.52 | 59.79 | 22.65 | 72.33 | 51.56 | 71.17 | 63.44 |
Inventory Days | 159.97 | 104.29 | 74.71 | 105.14 | 111.70 | 71.92 | 84.82 | 137.46 | 92.33 | 124.92 | 99.63 | 125.53 |
Days Payable | 146.63 | 73.69 | 38.26 | 54.75 | 131.52 | 75.76 | 46.42 | 15.85 | 92.57 | 71.19 | 83.28 | 52.16 |
Cash Conversion Cycle | 72.96 | 73.06 | 101.68 | 107.07 | 54.46 | 67.67 | 98.19 | 144.26 | 72.09 | 105.28 | 87.52 | 136.80 |
Working Capital Days | 60.79 | 34.82 | 56.87 | 56.55 | 57.68 | 49.20 | 52.48 | 70.77 | 68.54 | 79.83 | 76.94 | 196.14 |
ROCE % | 11.87% | 18.58% | 25.85% | 22.26% | 24.81% | 58.78% | 46.03% | 31.55% | 37.64% | 27.75% | 13.46% | 7.41% |
Documents
Announcements
- Corporate Action-Board approves Dividend 8h
-
Audited Standalone & Consolidated Financial Statements & Results For The Quarter And Year Ended 31St March 2025
8h - Audited FY25 results approved; Kalichem fully acquired; final 10% dividend recommended.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 20Th May 2025
9h - Approved FY25 audited results; recommended 10% final dividend subject to shareholder approval.
- Corporate Action-Board to consider Dividend 13 May
-
Board Meeting Intimation for Approval Of Audited Financial Statements And Results For The Quarter And Year Ended 31St March 2025, Recommendation Of Final Dividend, If Any And Any Other Business/ Agenda.
13 May - Board meeting on 20 May 2025 to approve FY25 results and consider final dividend.
Business Overview:[1]
CEL is an ISO 9001:2015, ISO 14001:2015 and ISO 50001:2018 certified company. It specializes in High Pressure Oxidation, Nitration, Chlorosulfonation and Amidation Chemistry - manufacturing intermediates
for bulk drugs(API), dyes & pigment, electro-plating, pharmaceuticals, dyes and pigments industries